Search
DE EN
more info

Contact:
Phone:+49 0761 1514 440 Fax:+49 0761 1514 460 Email: info@falkfoundation.org

Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 1/2026

Edition 4/2025

Edition 3/2025

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Esophagus to Small Intestine

Biomarker risk stratification with capsule sponge in the surveillance of Barrett’s oesophagus: Prospective evaluation of UK real-world implementation

Lancet. 2025;406(10500):271-282

Tan WK, Ross-Innes CS, Somerset T, Markert G, Markowetz F, O’Donovan M, di Pietro M, Sasieni P, Fitzgerald RC; DELTA consortium

Esophagus to Small Intestine

Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer

N Engl J Med. 2025;393(4):336-348

Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators

Esophagus to Small Intestine

TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51-FFCD-GASTFOX): An open-label, multicentre, randomised, phase 3 trial

Lancet Oncol. 2025;26(6):732-744

Zaanan A, Bouché O, de la Fouchardière C, Le Malicot K, Pernot S, Louvet C, Artru P, Le Brun Ly V, Aldabbagh K, Khemissa-Akouz F, Lecomte T, Castanie H, Laly M, Botsen D, Roth G, Samalin E, Muller M, Breysacher G, Manfredi S, Phelip JM, Taieb J

Esophagus to Small Intestine

Tirzepatide as compared with semaglutide for the treatment of obesity

N Engl J Med. 2025;393(1):26-36

Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators

Esophagus to Small Intestine

Coadministered cagrilintide and semaglutide in adults with overweight or obesity

N Engl J Med. 2025;393(7):635-647

Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; REDEFINE 1 Study Group

Esophagus to Small Intestine

Oral semaglutide at a dose of 25 mg in adults with overweight or obesity

N Engl J Med. 2025;393(11):1077-1087

Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT; OASIS 4 Study Group

Esophagus to Small Intestine

Capsule endoscopy-guided proactive treat-to-target versus continued standard care in patients with quiescent Crohn’s disease: A randomized controlled trial

Gastroenterology. 2025;169(1):85-93.e3

Ben-Horin S, Lahat A, Ungar B, Ukashi O, Yablecovitch D, Amitai MM, Haberman Y, Selinger L, Talan-Asher A, Kriger-Sharabi O, Naftali T, Ron Y, Yanai H, Dotan I, Kopylov U, Eliakim R; Israeli IBD Research Nucleus (IIRN)

Esophagus to Small Intestine

Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn’s disease: A phase 2a induction trial

Lancet Gastroenterol Hepatol. 2025;10(8):715-725

Feagan BG, Sands BE, Siegel CA, Dubinsky MC, Longman RS, Sabino J, Laurent O, Luo A, Lu J, Nguyen DD, Muñoz-Elias EJ, Llewellyn H, Wang Y, Jang I, Bilsborough J, Marchelletta R, Towfic F, Yen M, Anderson JK, DuVall A, Kierkus J, Woynarowski M, Al Kharrat H, Targan SR, McGovern DPB

Esophagus to Small Intestine

Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GRAVITI study

Gastroenterology. 2025;169(2):308-325

Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D’Haens G; GRAVITI Study Group